CoChat

Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice

Ma, De‐Lin, Chen, Fu‐Qiong, Xu, Wei‐Jie, Yue, Wen‐Zhu, Yuan, Gang, Yang, Yan · 2015 · Journal of Neurochemistry
Cited by 69

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Increasing evidence has shown that type 2 diabetes (T2D) is a risk factor for Alzheimer's disease. Neurofibrillary tangles, which consist of hyperphosphorylated tau and misfolded microtubules, is one of the neuropathological hallmarks of Alzheimer's disease. Db/db mice, a rodent model of T2D, also exhibited age‐dependent tau hyperphosphorylation. Glucagon‐like peptide‐1 (GLP‐1) mimetics, a type of drug used in T2D, has been found to have neuroprotective effects. The aim of this study was to explore the potential effects of liraglutide (a GLP‐1 analog), or insulin, on tau phosphorylation in T2D animals. Male db/db mice (3–3.5 weeks) were daily injected subcutaneously with liraglutide (n = 27), insulin (n = 27), or saline (n = 26), and five to seven mice were killed every 2 weeks for analysis of plasma and cerebrospinal (CSF) insulin levels by ELISA, and protein levels in the hippocampal formation by western blot. We found that db/db mice treated with saline exhibited an age‐dependent decrease in CSF insulin and an increase in hippocampal tau phosphorylation. Liraglutide injection reversed the CSF insulin to ~1 mIU/L by the end of 8 weeks treatment, and prevented the hyperphosphorylation of tau protein in the hippocampal formation. By contrast, insulin injection had no effects on CSF insulin or phosphorylation of tau protein. In summary, this study indicates that early GLP‐1 analog intervention prevented the age‐dependent tau hyperphosphorylation in T2D mice brain, probably by facilitating sequential activation in an insulin signaling pathway reflected in increased basal activation of Akt and basal suppression of glycogen synthase kinase‐3 beta. image We found that liraglutide, a GLP‐1 (glucagon‐like peptide‐1) analog, prevented the age‐dependent Alzheimer‐like tau hyperphosphorylation in diabetic db/db mice. We proposed that liraglutide crosses the blood–brain barrier, and binds GLP‐1 receptors from which G beta gamma dissociates intracellularly to activate PI3K, resulting in activation of Akt, which suppress GSK‐3β (glycogen synthase kinase‐3β), and thereby prevents it from phosphorylating tau. IRS‐1: insulin receptor substrate 1; IRS‐2: insulin receptor substrate 2; PI3K: phosphatidylinositol 3‐kinase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13248

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 69

Metadata

Authors
Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2015-08-11
Volume
135
Issue
2
Pages
301-308
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1955207589
Cited by
69
References
9
FWCI
4.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. https://app.cochat.ai/papers/10.1111/jnc.13248
The paper
Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015). Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.